Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.830
-0.200 (-6.60%)
At close: Mar 3, 2026, 4:00 PM EST
2.830
0.00 (0.00%)
After-hours: Mar 3, 2026, 4:53 PM EST
Protalix BioTherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Protalix BioTherapeutics stock has a target of 12, which predicts an increase of 324.03% from the current stock price of 2.83.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 21, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $12 | Strong Buy | Maintains | $15 → $12 | +324.03% | Nov 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +430.04% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +253.36% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +253.36% | Oct 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +147.35% | May 3, 2021 |
Financial Forecast
Revenue This Year
58.56M
from 53.40M
Increased by 9.67%
Revenue Next Year
72.53M
from 58.56M
Increased by 23.86%
EPS This Year
0.03
from 0.04
Decreased by -31.11%
EPS Next Year
0.18
from 0.03
Increased by 600.00%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 65.1M | 83.1M | |
| Avg | 58.6M | 72.5M | |
| Low | 52.9M | 63.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 21.9% | 42.0% | |
| Avg | 9.7% | 23.9% | |
| Low | -0.9% | 7.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.03 | 0.21 | |
| Avg | 0.03 | 0.18 | |
| Low | 0.02 | 0.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -14.1% | 731.7% | |
| Avg | -31.1% | 600.0% | |
| Low | -46.5% | 482.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.